DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20163322

Role of glycated hemoglobin (HBA1c) as a dual marker to predict glycemic status and dyslipidemia in type II diabetes mellitus

Mangala Sirsikar, Supriya S, Shrabani Mohanty, Venkata Bharat Kumar Pinnelli

Abstract


Background: Type 2 diabetes mellitus (DM) is an endocrinological disease associated with hyperglycemia characterized by both insulin resistance and defective insulin secretion. Glycated hemoglobin (HbA1c) is a routinely used marker for long-term glycemic control. This study is aimed at investigating the relationship between glycemic control and serum lipid profile and to evaluate the role of glycated haemoglobin as an independent risk factor for cardiovascular diseases in patients with type-2 diabetes and to evaluate the diagnostic value of glycated hemoglobin (HbA1c) in predicting diabetic dyslipidemia as a marker of circulating lipids. The aim of the present study was to estimate glycated hemoglobin and lipid profile in patients with type 2 DM and compare it with controls (healthy subjects). The association of glycated hemoglobin with lipid profile evaluated.

Methods: This study was conducted in 150 subjects, out of whom 75 were type 2 diabetes mellitus patients (cases) and 75 were non diabetic healthy subjects (controls).The sera were analyzed for HbA1c, fasting blood glucose (FBG), total cholesterol, triglycerides, high-density lipoprotein cholesterol (HDL) and low-density lipoprotein cholesterol (LDL).

Results: A significantly increased level of glycated hemoglobin (HbA1c) is observed in cases compared to control. HbA1c showed direct and significant correlations with cholesterol, triglycerides and LDL and inverse correlation with HDL in cases when compared to controls. Our study also revealed a significant positive correlation between lipid profile and glycated hemoglobin.

Conclusions: These findings clearly suggest that HbA1c can provide valuable supplementary information about the extent of circulating lipids besides its primary role in monitoring long-term glycemic control. Further studies are warranted to reinforce the potential of HbA1c as a biomarker for screening of high-risk diabetic patients.


Keywords


Type 2 diabetes mellitus, Glycated hemoglobin HbA1c, Circulating lipids, Diabetic dyslipidemia

Full Text:

PDF

References


Hameed IK, Abed BA, Rashid NF. Glycated hemoglobin as a dual marker associated between HbA1c and dyslipidemia in type 2 diabetic patients. J Fac Med Baghdad. 2012;54:88-92.

Mahato RV, Gyawali P, Raut PP, Regmi P, Singh KP, Pandeya DR, et al. Asociated between glycemic control and serum lipid Profile in type 2 diabetic patients: Glycated hemoglobin as a dual biomarker. Biomedical research. 2011;22(3):375-80.

Sultan A, Thuan JF, Avignon. A Primary prevention of cardiovascular events and type 2 diabetes: should we prioritize our interventions? Diabetes Metab. 2006;32:559-67.

Amini M, Horri N, Zare M, Haghighi S, Hosseini SM, Aminorroaya A, et al. People with impaired glucose tolerance and impaired fasting glucose are similarly susceptible to cardiovascular disease: a study in first-degree relatives of type 2 diabetic patients. Ann Nutr Metab. 2010;56(4):267-72.

American diabetes association. Implications of the United Kingdom prospective diabetes study. Diabetes care. 2003;26 (Suppl. 1):28- 32

Campbell RK. Type 2 diabetes: Where we are today: An overview of disease burden, current treatments, and treatment strategies. J Am Pharm Assoc. 2009;49 (Suppl 1):S3-9.

Wilson PWF, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97(18):1837-47.

The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA. 1984;251(3):351-64.

National Cholesterol Education Program (NCEP). Lipid Panel Reference Ranges: Pathology,inc. 2011.

Ken Sikaris. The Correlation of Hemoglobin A1c to Blood Glucose. J Diab Sci Tech. 2009;3:429-38.

Wan EY, Fong DY, Fung CS, Lam CL. Incidence and predictors for cardiovascular disease in Chinese patients with type 2 diabetes mellitus - a population-based retrospective cohort study. J Diab Compli. 2016;30(3):444-50.

West NA, Hamman RF, Mayer-Davis EJ, D'Agostino RB Jr, Marcovina SM, Liese AD, et al. Cardiovascular risk factors among youth with and without type 2 diabetes : differences and possible mechanisms. Diabetes Care. 2009;32(1):175-80.

Gotto AM Jr. Cardiologist’s role in improving glucose control and global cardiovascular risk in patients with type 2 diabetes mellitus. Am J Cardiol. 2007:99:3-5.

Ravipati G, Aronow WS, Ahn C, Sujata K, Saulle LN, Weiss MB. Association of hemoglobin A1c level with the severity of coronary artery disease in patients with diabetes mellitus. Am J Cardiol. 2006;97:968-9.

Kawasumi M, Tanaka Y, Uchino H, Shimizu T, Tamura Y, et al. Strict glycemic control ameliorates the increase of carotid IMT in patients with type 2 diabetes. Endocr J. 2006;53:45-50.

DCCT Research Group. The absence of a glycemic threshold for the development of long-term complications: the perspective of the diabetes control and complications trial. Diabetes. 1996;45(10):1289-98.

Avogaro A, Giorda C, Maggini M, Mannucci E, Raschetti R, Lombardo F, et al. Incidence of coronary heart disease in type 2 diabetic men and women: impact of microvascular complications, treatment and geographic location. Diabetes Care. 2007;30(5):1241-7.

Smellie WS. Hypertriglyceridaemia in diabetes. BMJ. 2006;333(7581):1257-60.

Ladeia AM, Adan L, Couto-Silva AC, Hiltner A, Guimaraes AC. Lipid profile correlates with glycemic control in young patients with type 1 diabetes mellitus. Prev Cardiol. 2006;9(2):82-8.

Chan WB, Tong PC, Chow CC, So WY, Ng MC, Ma RC, et al. Triglyceride predicts cardiovascular mortality and its relationship with glycemia and obesity in Chinese type 2 diabetic patients. Diabetes Metab Res Rev. 2005;21(2):183-8.

Hanefeld M, Fischer S, Julius U, Schulze J, Schwanebeck U, Schmechel H, et al. Risk Factors for myocardial infarction and death in newly detected NIDDM: the Diabetes intervention study, 11-year follow-up. Diabetologia. 1996;39(12):1577-83.

Goldberg IJ. Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolism and atherogenesis. J Lipid Res. 1996;37(4):693-707.

Kalofoutis C, Piperi C, Zisaki A, Singh J, Harris F, Phoenix D, et al. Differences in expression of cardiovascular risk factors among type 2 diabetes mellitus patients of different age. Ann N Y Acad Sci. 2006;1084:166-77.

Petitti DB, Imperatore G, Palla SL, Daniels SR, Dolan LM, Kershnar AK, et al. Serum lipids and glucose control: the SEARCH for Diabetes in Youth study. Arch PediatrAdolesc Med. 2007;161(2):159-65.

Khan HA. Clinical significance of HbA1c as a marker of circulating lipids in male and female type 2 diabetic patients. Acta Diabetol. 2007;44:193-200.

Nishimura R, Nakagami T, Sone H, Ohashi Y, Tajima N. Relationship between HbA1c and cardiovascular disease in mild-to moderate hyper-cholesterolemic Japanese individuals: subanalysis of a large-scale randomized controlled trial. Cardiovascular Diabetology. 2011;10:58.

Giansanti R, Rabini RA, Romagnoli F, Fumelli D, Sorichetti P, Boemi M, et al. Coronary heart disease, type 2 diabetes mellitus and cardiovascular disease risk factors: a study on a middle-aged and elderly population. Arch Genontol Geriatr. 1999:29:175-82.

Onat A, Sari I, Yazici M, Can G, Hergenc G, Avci GS. Plasma triglycerides, an independent predictor of cardiovascular disease in men: a prospective study based on a population with prevalent metabolic syndrome. Int J Cardiol. 2006:108:89-95.

Taylor KG, John WC, Mathews KA, Wright AD. A prospective study on the effect of 12 months treatment on serum lipids and apolipoproteins A-I, A-II and B in type II (non-insulin dependent) Diabetologia. 1982; 23(6):507-10.

Witztum JL, Mahoney EM, Branks MJ, Fisher M, Elam R, Steinberg D. Non enzymatic glucosylation of low-density lipoprotein alters its biologic activity. Diabetes. 1982;31(4 Pt 1):283-91.

Singla S, Kaur K, Kaur G, Kaur H, Kaur J, Jaswal S. lipoprotein (a) in type 2 diabetes mellitus: Relation to LDLc: HDLc ratio and glycemic control :Int J. Diab Dev Ctries 2009;29(2):80-4.

Gowtham K, Gandhe MB, Salwe KJ, Srinivasan AR. HDL/LDL Ratio As a Risk Factor In Type 2 Diabetes Mellitus : Advance Laboratory Medicine Internatonal. 2012;2(1):9-18.

Indumati.V, Patil VS, Krishnaswamy, Kumar S, Vijay V, Mahesh S, Rajeshwari V. NON-HDL choleaterol and LDL-C/HDL-C Ratio In Type II Diabetic patients. International Journal of Pharma and Bio Sciences. 2011;2:71-7.